Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis

(2017) Sarah Cargnin et al.   Journal of Thoracic Oncology

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

(2016) J. C. Thompson et al.   CLINICAL CANCER RESEARCH

Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma

(2016) Liqiang Xi et al.   CLINICAL CANCER RESEARCH

Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline

(2016) Anne C. Knol et al.   EXPERIMENTAL DERMATOLOGY

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma

(2016) Max Schreuer et al.   MELANOMA RESEARCH

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing

(2016) Matthew C. Hiemenz et al.   PLoS One

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

(2016) Jeanne Tie et al.   Science Translational Medicine

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

A novel approach for next-generation sequencing of circulating tumor cells

(2016) Stephanie S. Yee et al.   Molecular Genetics & Genomic Medicine

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis

(2016) Pamela J. Kaisaki et al.   PLoS One

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

(2015) C. Krepler et al.   CLINICAL CANCER RESEARCH

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

(2015) Maria Gonzalez-Cao et al.   MELANOMA RESEARCH

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma

(2015) M. R. Girotti et al.   Cancer Discovery

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

(2015) Elin S. Gray et al.   Oncotarget

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

(2015) Simon Chang-Hao Tsao et al.   Scientific Reports

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

(2014) S. Couraud et al.   CLINICAL CANCER RESEARCH

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Isolation and Molecular Characterization of Circulating Melanoma Cells

(2014) Xi Luo et al.   Cell Reports

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

(2014) Evan J Lipson et al.   Journal for ImmunoTherapy of Cancer

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets

(2013) Robert Daber et al.   Cancer Genetics

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma

(2012) Leila Khoja et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Circulating cell-free DNA in plasma of melanoma patients: Qualitative and quantitative considerations

(2011) Pamela Pinzani et al.   CLINICA CHIMICA ACTA

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

(2011) Matthew G. Krebs et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

(2009) S. J. Cohen et al.   ANNALS OF ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER